ClinicalTrials.gg
Not yet recruitingNCT06738043Updated Apr 9, 2026

Dexmedetomidine Versus Ketamine as Adjuvants in Bariatric Surgery

An interventional study of Dexmedetomidine infusion and Ketamine infusion in Obesity, Postoperative Pain and Bariatric Surgery, sponsored by Tanta University. Not yet recruiting. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing dexmedetomidine in Obesity — 2 open to participants now, 2 under way, none of them phase 3. Dexmedetomidine · Obesity.

Planned enrollment
3rd of 13
90 · median 60
Started
2026
the only one that year
No phase
6 of 13
2 open now
Registered
13th of 13
by date

Among the 13 studies testing dexmedetomidine in Obesity, this one is the 3rd largest by planned enrollment, is the only one that started in 2026, is one of 6 with no phase, and was the 13th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 13 studies testing dexmedetomidine in Obesity are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing dexmedetomidine in Obesity, or all of them as a file.
02

Study summary

This randomized controlled trial aims to compare the analgesic efficacy of dexmedetomidine infusion versus low-dose ketamine infusion as adjuvants in bariatric surgery. The study includes 90 patients undergoing bariatric surgery at Menoufia University Hospital, randomized into three groups: dexmedetomidine, ketamine, and control (placebo). Primary outcomes include total morphine consumption intra- and post-operatively. Secondary outcomes include postoperative pain scores, total analgesic consumption, time to first analgesic request, hemodynamic parameters, and patient satisfaction. This study seeks to explore safer, more effective pain management strategies to minimize opioid use in bariatric surgery patients.

Read the detailed description

This study is a prospective, randomized controlled interventional trial evaluating the analgesic efficacy and opioid-sparing effects of dexmedetomidine and low-dose ketamine as adjuvants in bariatric surgery. Ninety patients meeting the inclusion criteria will be enrolled and randomized into three groups:

  • Dexmedetomidine Group: Patients will receive a bolus dose of dexmedetomidine (0.5 µg/kg) followed by a continuous infusion (0.5 µg/kg/h) until 10 minutes before the end of surgery.
  • Ketamine Group: Patients will receive a bolus dose of ketamine (0.3 mg/kg) followed by a continuous infusion (0.3 mg/kg/h) until 10 minutes before the end of surgery.
  • Control Group: Patients will receive an equal volume of normal saline as a placebo.

Objectives

The primary objective is to compare intra- and postoperative morphine consumption between groups. Secondary objectives include:

  • Pain assessment using the Numeric Rating Scale (NRS) at multiple time points postoperatively.
  • Time to first request for rescue analgesia.
  • Hemodynamic stability (heart rate and mean arterial pressure).
  • Patient satisfaction assessed using a 5-point scale.
  • Incidence of adverse effects such as nausea, vomiting, bradycardia, and respiratory depression.

Study Protocol All patients will undergo standard preoperative assessments, including history, physical examination, and laboratory investigations. General anesthesia will be induced and maintained per institutional protocols. Postoperatively, pain management will follow a stepwise approach, with intravenous paracetamol as rescue analgesia.

Significance Given the high prevalence of obesity-related comorbidities, bariatric surgery patients are at increased risk for postoperative complications, particularly with opioid use. This study addresses the need for opioid-sparing pain management strategies, potentially reducing the risks of opioid-related adverse effects and improving patient outcomes.

03

Conditions studied

  • Obesity
  • Postoperative Pain
  • Bariatric Surgery

Keywords

  • Dexmedetomidine
  • Ketamine
  • Opioid-Sparing Analgesia
  • Randomized Controlled Trial
  • Pain Management
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18-60 years.
  • Both sexes.
  • (BMI) > 35 kg/m², scheduled for bariatric surgery.
  • (ASA) physical status I-II.

Exclusion criteria

Exclusion Criteria:

  • History of to dexmedetomidine or ketamine.
  • History of substance abuse or chronic opioid use.
  • (ASA) physical status III or IV.
  • Severe hepatic or renal impairment.
  • Cardiopulmonary disorders.
  • Severe diabetes mellitus.
  • Psychiatric disorders, seizures, uncontrolled hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg), or heart block.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine Group

    Participants in this group will receive a bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline over 10 minutes before induction of anesthesia. This will be followed by a continuous infusion of dexmedetomidine at 0.5 µg/kg/h until 10 minutes before the end of surgery.

    Drug: Dexmedetomidine infusion

  • Experimental
    Ketamine Group

    Participants in this group will receive a bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline over 10 minutes before induction of anesthesia. This will be followed by a continuous infusion of ketamine at 0.3 mg/kg/h until 10 minutes before the end of surgery.

    Drug: Ketamine infusion

  • Placebo comparator
    Control Group

    Participants in this group will receive a bolus dose of 0.9% normal saline over 10 minutes before induction of anesthesia. This will be followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.

    Drug: Normal Saline Infusion (Placebo)

Interventions

  • DrugDexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A bolus dose of dexmedetomidine (0.5 µg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.5 µg/kg/h until 10 minutes before the end of surgery.

  • DrugKetamineStudies of KetamineKetamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A bolus dose of ketamine (0.3 mg/kg ideal body weight) diluted in 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion at 0.3 mg/kg/h until 10 minutes before the end of surgery.

  • DrugNormal Saline Infusion (Placebo)

    A bolus dose of 0.9% normal saline is infused over 10 minutes before induction of anesthesia, followed by a continuous infusion of 0.9% normal saline until 10 minutes before the end of surgery.

06

What researchers measure

Primary outcomes

  1. Postoperative Total Morphine Consumption

    The total dose of morphine, measured in mg, administered to each participant during the first 24 hours postoperatively for pain control.

    Time frame: Within the first 24 hours postoperatively

Secondary outcomes

  1. Postoperative Pain Scores (Numeric Rating Scale - NRS)

    Pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be recorded at specific intervals postoperatively (1, 2, 4, 8, 12, 16, and 24 hours).

    Time frame: At 1, 2, 4, 8, 12, 16, and 24 hours postoperatively

  2. Time to First Request for Rescue Analgesia

    The duration (in hours) from the end of surgery to the first request for rescue analgesia (intravenous morphine) by the participant.

    Time frame: 24 hours postoperatively

  3. Hemodynamic Stability (Heart Rate)

    Heart rate (HR) will be monitored and recorded at specific intervals during and after surgery to assess hemodynamic stability.

    Time frame: From baseline (pre-surgery) to 24 hours postoperatively

  4. Hemodynamic Stability (Mean Arterial Pressure)

    Mean arterial pressure (MAP) will be monitored and recorded at specific intervals during and after surgery to assess hemodynamic stability.

    Time frame: From baseline (pre-surgery) to 24 hours postoperatively

  5. Total Analgesic Consumption (Other Than Morphine)

    The total dose of non-morphine analgesics (e.g., paracetamol) administered postoperatively to manage pain within the first 24 hours after surgery.

    Time frame: At 24 hours postoperatively

  6. Patient Satisfaction with Pain Management

    Patient satisfaction will be assessed using a 5-point Likert scale (1 = highly satisfied, 2 = satisfied, 3 = neutral, 4 = unsatisfied, 5 = highly unsatisfied) based on their postoperative pain management experience.

    Time frame: At 24 hours postoperatively

  7. Intraoperative Fentanyl Consumption

    The total dose of fentanyl, measured in µg, administered intraoperatively during anesthesia maintenance.

    Time frame: Intraoperatively (From induction of anesthesia until the end of surgery)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD and supporting information will be available starting 6 months after publication of the study results and will remain accessible for 5 years.

Access criteria: Access to IPD and supporting information will be provided to qualified researchers upon reasonable request. Requests should include a proposal outlining the intended research objectives, ethical approval, and a data-sharing agreement. Access will be granted via secure data transfer or repository.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Dec 17, 2024
StartEst.
Apr 20, 2026
Primary completionEst.
Apr 20, 2027
CompletionEst.
Apr 20, 2027
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06738043
Lead sponsor
Tanta University
Responsible party
Ahmed Abdalla Shalaby (Anesthesiology, Intensive Care and Pain Management Resident, Menoufia University) — Principal investigator
First posted
Dec 17, 2024
Start date
Apr 20, 2026 (estimated)
Primary completion
Apr 20, 2027 (estimated)
Completion
Apr 20, 2027 (estimated)
Last update
Apr 9, 2026

Study contacts

Ahmed A Shalaby, M.B.B.Ch
Contact
phdoc97@gmail.com
01020479848 ext. +2

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Ketamine

Start the discussion